Should aspirin be discontinued before surgery in a patient with a platelet count of 900 × 10⁹/L?

Management of Aspirin Before Surgery in a Patient with Platelet Count of 900 × 10⁹/L

The decision to hold aspirin before surgery should be based primarily on the bleeding risk of the specific procedure and the indication for aspirin therapy, NOT on the platelet count of 900 × 10⁹/L alone. A platelet count of 900 × 10⁹/L does not automatically mandate aspirin discontinuation, as this decision requires weighing thrombotic versus bleeding risks specific to the clinical context.

Risk-Stratified Approach to Aspirin Management

For High Bleeding Risk Procedures

Discontinue aspirin 3 days before the procedure (last dose on Day -3), or 5 days for intracranial neurosurgery (last dose on Day -5). 1

• High bleeding risk procedures include intracranial neurosurgery, posterior spinal surgery, and other procedures where even minor bleeding causes severe complications 1
• The goal is complete correction of platelet function inhibited by aspirin in all patients undergoing these procedures 1
• Resume aspirin as soon as possible postoperatively according to bleeding risk 1

For Intermediate and Low Bleeding Risk Procedures

The management depends critically on the indication for aspirin therapy:

Primary Prevention

• Discontinue aspirin preoperatively 1
• Aspirin should not be initiated perioperatively for primary prevention (except carotid endarterectomy) 1

Secondary Prevention (Cardiovascular Disease, Stroke, Peripheral Artery Disease)

• Continue aspirin throughout the perioperative period 1
• Discontinuation of aspirin in secondary prevention patients is associated with increased thrombotic events, including recurrent stroke and cardiovascular events 1
• The POISE-2 trial showed aspirin continuation did not increase bleeding risk in most patients, though it included predominantly low-risk patients 1

Coronary Artery Surgery

• Continue aspirin throughout the perioperative period 1
• Aspirin reduces perioperative myocardial infarction in coronary surgery, though at the cost of increased bleeding and transfusion 1

Patients with Coronary Stents

• Elective surgery should be delayed 30 days after bare-metal stent (BMS) and optimally 6 months after drug-eluting stent (DES) 2, 3
• If surgery cannot be delayed: continue aspirin if possible and involve multidisciplinary discussion 4, 2, 3
• For drug-eluting stents requiring surgery between 3-6 months, surgery may be considered if delay risk exceeds stent thrombosis risk 3

Special Considerations for Thrombocytosis (Platelet Count 900 × 10⁹/L)

Essential Thrombocythemia Context

If this elevated platelet count represents essential thrombocythemia or myeloproliferative neoplasm:

• Aspirin response may be impaired at higher platelet counts 5
• Patients with platelet counts ≥317 × 10⁹/L showed higher rates of high on-treatment residual platelet reactivity to aspirin 5
• The extent of platelet inhibition by aspirin depends partly on the platelet count in myeloproliferative neoplasms 5
• Consider twice-daily aspirin dosing in essential thrombocythemia patients to maintain 24-hour platelet inhibition, as once-daily dosing may not provide adequate suppression throughout the dosing interval 6, 7

Bleeding Risk with Extreme Thrombocytosis

• Platelet counts >1,500 × 10⁹/L carry increased bleeding risk and represent a clear indication for platelet-reductive therapy 8
• At 900 × 10⁹/L, the primary concern is thrombotic rather than bleeding risk 8
• Simple observation may be preferred over aspirin prophylaxis in low-risk patients with platelet counts >1,000 × 10⁹/L harboring CALR mutations 6

Common Pitfalls to Avoid

• Do not automatically discontinue aspirin based solely on platelet count - the decision requires assessment of procedure bleeding risk and aspirin indication 1
• Do not use bridging with heparin or LMWH when discontinuing aspirin - this promotes bleeding without clear benefit 1
• Do not reduce aspirin dose perioperatively in patients on long-term therapy up to 300 mg/day 1
• Avoid using enteric-coated aspirin in essential thrombocythemia patients, as some display poor responsiveness to this formulation 6
• Do not delay resumption of aspirin postoperatively - restart as soon as hemostasis permits 1, 3

Algorithm Summary

1. Identify aspirin indication: Primary vs. secondary prevention vs. coronary stent
2. Assess surgical bleeding risk: High (neurosurgery) vs. intermediate vs. low
3. For secondary prevention + intermediate/low bleeding risk: Continue aspirin
4. For high bleeding risk procedures: Discontinue aspirin 3-5 days preoperatively
5. For primary prevention: Discontinue aspirin
6. If myeloproliferative neoplasm: Consider platelet function testing and twice-daily dosing regimen
7. Resume aspirin postoperatively as soon as bleeding risk permits